Haematological malignancies

Explore our latest news, features and educational resources in this specialist area.

Brentuximab vedotin in combination recommended for untreated systemic anaplastic large cell lymphoma

Regulatory Alerts, Cancer, Oncology, Haematological malignancies, Oncology Room

Brentuximab vedotin in combination recommended for untreated systemic anaplastic large cell lymphoma

Aug 12, 2020

$Gilteritinib recommended for relapsed or refractory acute myeloid leukaemia$

Regulatory Alerts, Cancer, Oncology, Haematological malignancies, Oncology Room

Gilteritinib recommended for relapsed or refractory acute myeloid leukaemia

Aug 12, 2020

Treosulfan with fludarabine recommended for malignant disease before allogeneic stem cell transplant

Regulatory Alerts, Cancer, Oncology, Haematological malignancies, Oncology Room

Treosulfan with fludarabine recommended for malignant disease before allogeneic stem cell transplant

Aug 05, 2020

NICE does not recommend chlormethine gel for type of lymphoma

Regulatory Alerts, Cancer, Oncology, Haematological malignancies, Oncology Room

NICE does not recommend chlormethine gel for type of lymphoma

Aug 05, 2020

Gilteritinib recommended for relapsed or refractory acute myeloid leukaemia

Regulatory Alerts, Cancer, Oncology, Haematological malignancies, Oncology Room

Gilteritinib recommended for relapsed or refractory acute myeloid leukaemia

Jul 16, 2020

Haematology – Journal Spy

Journal Spy, Haematology, Haematological malignancies

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility.

Jul 10, 2020

Haematology – Journal Spy

Journal Spy, Haematology, Haematological malignancies

Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.

Jul 03, 2020

Haematology – Journal Spy

Journal Spy, Haematology, Oncology, Haematological malignancies

Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.

Jun 26, 2020

Isatuximab in combination not recommended for multiple myeloma

Regulatory Alerts, Oncology, Haematological malignancies, Oncology Room

Isatuximab in combination not recommended for multiple myeloma

Jun 04, 2020

Haematology – Journal Spy

Journal Spy, Cancer, Haematology, Oncology, Haematological malignancies

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.

May 29, 2020

Haematology – Journal Spy

Journal Spy, Haematology, Oncology, Haematological malignancies

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.

May 22, 2020

Haematology – Journal Spy

Journal Spy, Cancer, Haematology, Oncology, Haematological malignancies

Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

May 16, 2020

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Oncology – Journal Spy

Haematology, Oncology, Haematological malignancies

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

Feb 06, 2020

Pattern of hospital visits offers clue to spotting people at risk of myeloma

NCRI Cancer Conference

News, Cancer, Oncology, Haematological malignancies

Pattern of hospital visits offers clue to spotting people at risk of myeloma

Nov 04, 2019